Direct Oral Anticoagulation vs. Warfarin for Cerebral Venous Thrombosis

Rates of bleeding, progressive CVT, and recurrent venous thromboembolism were similar with dabigatran or warfarin.

Hematologists have scarce evidence to draw from when anticoagulating patients with thrombosis in atypical sites, such as the splanchnic circulation or cerebral veins. Historically, most patients with atypical site thrombosis are treated with warfarin, whereas some receive direct oral anticoagulants (DOACs) off label. However, it is unknown if DOACs are as safe and effective as warfarin for such patients, especially those with cerebral venous thrombosis (CVT).

Now, investigators have conducted an industry-funded, international, open-label, randomized trial (RE-SPECT CVT) to evaluate rates of bleeding and recurrent CVT and venous thromboembolism (VTE) in 120 CVT patients (55% women; ages, 40–49; 90% presenting with headache) who received 24 we…

Reviewing Author

Brady L. Stein, MD, MHS

Disclosures

Leadership Positions in Professional SocietiesAmerican Society of Hematology (Senior Editor, ASH Self-Assessment Program; guideline development)

Brady L. Stein, MD, MHS

Disclosures

Leadership Positions in Professional SocietiesAmerican Society of Hematology (Senior Editor, ASH Self-Assessment Program; guideline development)

Direct Oral Anticoagulation vs. Warfarin for Cerebral Venous Thrombosis

Topics

Reviewing Author